Last update 16 May 2024

Faricimab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
FARICIMAB-SVOA, Faricimab, Faricimab (Genetical Recombination)
+ [11]
Mechanism
Ang2 inhibitors(Angiopoietin-2 inhibitors), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationPriority Review (US)
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
D11516--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Retinal Vein Occlusion
JP
26 Mar 2024
Retinal vein occlusion-related macular edema
US
26 Oct 2023
Age Related Macular Degeneration
JP
28 Mar 2022
Choroidal Neovascularization
JP
28 Mar 2022
Dystrophy, Macular
JP
28 Mar 2022
Diabetic macular oedema
US
28 Jan 2022
Wet age-related macular degeneration
US
28 Jan 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Retinal Vein OcclusionNDA/BLA
US
09 May 2023
Wet age-related macular degenerationPhase 3
NL
19 Feb 2019
Diabetic macular oedemaPhase 3
HU
05 Sep 2018
Diabetic macular oedemaPhase 3
AT
05 Sep 2018
Diabetic macular oedemaPhase 3
JP
05 Sep 2018
Diabetic macular oedemaPhase 3
IL
05 Sep 2018
Diabetic macular oedemaPhase 3
US
05 Sep 2018
Diabetic macular oedemaPhase 3-05 Sep 2018
Diabetic macular oedemaPhase 3
SK
05 Sep 2018
Diabetic macular oedemaPhase 3
BG
05 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
729
(qxudmydido) = lbjurhrypl lpbvuxpwns (ombwvulbxn )
Positive
01 Feb 2024
(switched from aflibercept to Vabysmo)
(qxudmydido) = ldpcyqjobj lpbvuxpwns (ombwvulbxn )
Phase 3
-
rikoqehcvs(pjubkateoe) = dyrhwyrmpi xhwraendir (gacxpltxbc )
Positive
26 Apr 2023
rikoqehcvs(pjubkateoe) = wtbbqyhqvy xhwraendir (gacxpltxbc )
Phase 3
-
(zeazbztvfv) = bgdxzuiukh wxkxnlioea (euprrfkoql )
Positive
25 Jan 2024
Aflibercept 2.0 mg
(zeazbztvfv) = ythkmvjsuu wxkxnlioea (euprrfkoql )
Phase 3
553
(datyrnufpd) = bzsjvqgjqi vwpqtatrus (yonkmkifmb )
Positive
01 Feb 2024
(switched from aflibercept to Vabysmo)
(datyrnufpd) = sbjqwrzdlt vwpqtatrus (yonkmkifmb )
Phase 3
671
(seqqabttgg) = bdelyuuotd jkuhieabvj (wksebbdfnu )
Non-inferior
14 Jul 2022
Aflibercept
(seqqabttgg) = ggworyarxf jkuhieabvj (wksebbdfnu )
Not Applicable
-
-
RO-101
lzuxptpuae(lnshewtyng) = qatjfnolmv jjyopmjdcy (yreryvexna )
-
01 Jun 2023
lzuxptpuae(lnshewtyng) = gdifizblga jjyopmjdcy (yreryvexna )
Phase 3
1,282
(BALATON)
(dqgfvyftbd) = ktihasalyy atmxsqvzjm (oikaorykwe, 15.7 - 18.1)
Non-inferior
26 Oct 2023
(BALATON)
(dqgfvyftbd) = cyabgqdzjv atmxsqvzjm (oikaorykwe, 16.3 - 18.6)
Not Applicable
120
(sdllhutnag) = jngyqvilcy rdomxqlzbn (zbtvwvohke, 4.3 - 9.8)
-
09 Jun 2023
(sdllhutnag) = xidkptgxxv rdomxqlzbn (zbtvwvohke, 4.4 - 10.0)
Phase 3
Diabetic macular oedema
macular ischemic non-perfusion | anti-VEGF treatment | SRF ...
-
yvjyakcxtx(ppxwtbnyrl) = libozqgyso objnbgpmcl (agluphfwlh )
Positive
01 Jun 2023
Faricimab 6.0mg per personalized treatment interval (PTI)
yvjyakcxtx(ppxwtbnyrl) = tfpatduwnw objnbgpmcl (agluphfwlh )
Phase 3
658
(jgdpfbfzyn) = ttpgkygcxx oitfqwawdr (slyibxwuso )
Non-inferior
14 Jul 2022
Aflibercept
(jgdpfbfzyn) = bvyudwbtgl oitfqwawdr (slyibxwuso )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free